register

News & Trends - MedTech & Diagnostics

New J&J cervical spine system to reduce procedural complexity and surgical costs

Health Industry Hub | November 25, 2019 |

The Johnson & Johnson Medical Devices Companies announced that DePuy Synthes has launched the SYMPHONY Occipito-Cervico-Thoracic (OCT) System, expanding its offering for the surgical treatment of conditions in the neck and upper back.

The SYMPHONY System includes a differentiated offering of instruments and implants designed for stabilisation of the spine in patients undergoing Posterior Cervical Fusion surgery. The announcement was made at the 47th annual Cervical Spine Research Society (CSRS) meeting.

Guided by research conducted in association with the International Spine Study Group, the SYMPHONY System is designed to improve surgeon experience in four key areas: fixation, alignment, targeting and extensions. The range of instrumentation offers options for surgeons to choose from and is compatible with navigation software to aid in targeting in challenging anatomy.

“The most interesting aspect of the SYMPHONY System is its ability to address highly complex needs that we face at the front lines of cervical spine surgery,” said Dr Christopher Ames, Spine Surgeon. “It also takes into account ways to create efficiencies for healthcare systems, making it a truly comprehensive offering.”

The SYMPHONY System was designed to improve fixation in patients with suboptimal bone quality, to address a potential cause of screw failure which may lead to revision surgery. By enabling crossing of the cervical to thoracic junction with one system, the SYMPHONY System reduces the number of instrument trays from six to two, which may provide cost savings in processing and sterilisation as well.1

The system combines the benefits of two market-leading posterior cervical systems—the SYNAPSE OCT System and MOUNTAINEER OCT System—uniting many of the patented features of those brands and building on their proven instrumentation.

You may also like QLD researchers discover blood test for deadly ocular melanoma

Register FREE to receive the latest news, innovations and insights from Health Industry Hub; the only one-stop-hub connecting Australia’s Pharma, MedTech and Biotech industry professionals and its key stakeholders.


News & Trends - Pharmaceuticals

Did the Federal Budget deliver for health?

Did the Federal Budget deliver for health?

Health Industry Hub | March 26, 2025 |

Health is the Federal Government’s largest financial commitment outside social welfare, absorbing approximately 15% of taxpayer funds. Yet, tonight’s Budget […]

More


News & Trends - Pharmaceuticals

How can the government Close the Gap with forecasted decline in funding?

How can the government Close the Gap with forecasted decline in funding?

Health Industry Hub | March 26, 2025 |

The Federal Government will increase investment in First Nations health programs by just 2.8% to $1.4 billion in 2025-26 – […]

More


News & Trends - Biotechnology

Local biotech kicks off phase 3 trial for lung cancer combination therapy

Local biotech kicks off phase 3 trial for lung cancer combination therapy

Health Industry Hub | March 26, 2025 |

ASX-listed biotech company Immutep has reached a major milestone, announcing that the first patient has been successfully dosed in its […]

More


Medical and Science

Research on life support as government Budget fails to deliver critical funding

Research on life support as government Budget fails to deliver critical funding

Health Industry Hub | March 26, 2025 |

Stakeholders are voicing disappointment over the government’s Budget failure to at least maintain research funding in line with inflation. In […]

More


This content is copyright protected. Please subscribe to gain access.